TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
A combination therapy of Docetaxel, Cisplatin und 5-Fluorouracil (= TPF) will be used in
patients with resectable oropharyngeal and cavity of the mouth cancer. To improve the
compatibility of the TPF-induction without decreasing the efficacy the dose will be given on
day 1 and 8 instead of applying the whole dose on day 1 every 3 weeks.
In the phase I-part of the trial the optimal therapeutic dose of Docetaxel and Cisplatin will
be defined.
In the phase II-part the progression-free survival after 2 years will be assessed in patients
treated with the optimal therapeutic dose.